Glass LM - Search Results

1

Spectrum of use and effectiveness of endoscopic and surgical therapies for chronic pancreatitis in the United States.

Glass LM, Whitcomb DC, Yadav D, Romagnuolo J, Kennard E, Slivka AA, Brand RE, Anderson MA, Banks PA, Lewis MD, Baillie J, Sherman S, Alkaade S, Amann ST, Disario JA, O'Connell M, Gelrud A, Forsmark CE, Gardner TB; North American Pancreatic Study Group. Glass LM, et al. Pancreas. 2014 May;43(4):539-43. doi: 10.1097/MPA.0000000000000122. Pancreas. 2014. PMID: 24717802 Free PMC article.

2

Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults.

Gardner TB, Glass LM, Smith KD, Ripple GH, Barth RJ, Klibansky DA, Colacchio TA, Tsapakos MJ, Suriawinata AA, Tsongalis GJ, Pipas JM, Gordon SR. Gardner TB, et al. Among authors: glass lm. Am J Gastroenterol. 2013 Oct;108(10):1546-50. doi: 10.1038/ajg.2013.103. Am J Gastroenterol. 2013. PMID: 24091499 Free PMC article.

3

Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis.

Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Saeed N, et al. Transplantation. 2019 Nov;103(11):e345-e354. doi: 10.1097/TP.0000000000002916. Transplantation. 2019. PMID: 31415032

4

Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis.

Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, Toor A. Glass LM, et al. Dig Dis Sci. 2015 Apr;60(4):1024-30. doi: 10.1007/s10620-014-3380-3. Epub 2014 Oct 30. Dig Dis Sci. 2015. PMID: 25354830

5

Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.

Patel YA, Gifford EJ, Glass LM, McNeil R, Turner MJ, Han B, Provenzale D, Choi SS, Moylan CA, Hunt CM. Patel YA, et al. Among authors: glass lm. Aliment Pharmacol Ther. 2018 Jan;47(2):268-278. doi: 10.1111/apt.14411. Epub 2017 Nov 8. Aliment Pharmacol Ther. 2018. PMID: 29115682 Free PMC article.

6

Disease Knowledge, Health-Related Quality of Life, and Lifestyle Behavior Change in Patients with Nonalcoholic Fatty Liver Disease: Impact of an Educational Intervention.

Glass L, Asefa H, Volk M, Lok AS, Tincopa MA. Glass L, et al. Dig Dis Sci. 2022 Jun;67(6):2123-2133. doi: 10.1007/s10620-021-07052-9. Epub 2021 May 27. Dig Dis Sci. 2022. PMID: 34043121

7

Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey.

Saeed N, Glass LM, Habbal H, Mahmood A, Sengstock D, Saini SD, Tincopa MA. Saeed N, et al. Among authors: glass lm. Therap Adv Gastroenterol. 2021 Sep 20;14:17562848211042200. doi: 10.1177/17562848211042200. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34567270 Free PMC article.

8

Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.

Patel YA, Gifford EJ, Glass LM, Turner MJ, Han B, Moylan CA, Choi S, Suzuki A, Provenzale D, Hunt CM. Patel YA, et al. Among authors: glass lm. Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19. Dig Dis Sci. 2018. PMID: 29779083

9

Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?

Glass LM, Hunt CM, Fuchs M, Su GL. Glass LM, et al. Fed Pract. 2019 Feb;36(2):64-71. Fed Pract. 2019. PMID: 30867626 Free PMC article.

10

Evidence-Based Therapeutic Options for Hepatorenal Syndrome.

Glass L, Sharma P. Glass L, et al. Gastroenterology. 2016 Apr;150(4):1031-3. doi: 10.1053/j.gastro.2016.02.050. Epub 2016 Feb 27. Gastroenterology. 2016. PMID: 26922867 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page